Curis to Present at Upcoming Healthcare Conference in July

Curis, a biotechnology company listed on NASDAQ under the ticker CRIS, announced that its President and CEO, James Dentzer, will present at the Jones Healthcare Seaside Summit 2024.

Rhea-AI Summary

Curis, a biotechnology company listed on NASDAQ under the ticker CRIS, announced that its President and CEO, James Dentzer, will present at the Jones Healthcare Seaside Summit 2024. The presentation is scheduled for July 15, 2024, at 8:00 a.m. PT (11:00 a.m. ET). Curis focuses on developing emavusertib (CA-4948), an orally available small molecule IRAK4 inhibitor. A live webcast and an archived replay of the presentation will be accessible through the Events & Presentations section of Curis's website.

Argus Session date unavailable

+0.29% session move Open Argus

Details

News Market Reaction – CRIS

The recorded move for CRIS in the trading session of this news was +0.29%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LEXINGTON, Mass., July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present at the Jones Healthcare Seaside Summit 2024 on July 15, 2024 at 8:00 a.m. PT (11:00 a.m. ET). A live webcast and archived replay will be available and can be accessed here or on the Events & Presentations section of Curis's website.

About Curis, Inc.

Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS) with either a FLT3 mutation or a splicing factor mutation (U2AF1 or SF3B2), and as a frontline combination therapy with azacitidine and venetoclax in patents with AML. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML and MDS. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-present-at-upcoming-healthcare-conference-in-july-302192752.html

SOURCE Curis, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Curis present at the Jones Healthcare Seaside Summit 2024?

Curis will present at the Jones Healthcare Seaside Summit 2024 on July 15, 2024, at 8:00 a.m. PT (11:00 a.m. ET).

Who will represent Curis at the Jones Healthcare Seaside Summit 2024?

James Dentzer, the President and CEO of Curis, will represent the company at the Jones Healthcare Seaside Summit 2024.

What is emavusertib (CA-4948) developed by Curis?

Emavusertib (CA-4948) is an orally available, small molecule IRAK4 inhibitor developed by Curis.

Where can I access the webcast of Curis's presentation at the Jones Healthcare Seaside Summit 2024?

A live webcast and archived replay of Curis's presentation will be available on the Events & Presentations section of Curis's website.

What is the stock symbol for Curis?

The stock symbol for Curis is CRIS.